PDS Biotechnology Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frank K. Bedu-Addo
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 303A College Road East Princeton NJ United States of America 08540
- IPO Date
- Sep 30, 2015
- CIK
- 0001472091
- Website
- pdsbiotech.com
- Similar Companies
- Business
- PDS Biotechnology Corporation (NasdaqGS: PDSB), a clinical-stage immunotherapy company, develops targeted cancer immunotherapies based on its proprietary Versamune platform technology, which activates and directs T-cell responses against tumors; the company also advances PDS01ADC, a tumor-targeted antibody-drug conjugate that delivers interleukin-12 to suppress tumor defenses while enhancing T-cell infiltration and potency. Its lead candidate, PDS0101 (Versamune HPV), targets HPV16-positive cancers including head and neck squamous cell carcinoma, cervical, anal, and oropharyngeal cancers, either as monotherapy or in combinations with checkpoint inhibitors like pembrolizumab or chemoradiotherapy; additional pipeline programs include PDS0301, an IL-12 conjugate for advanced solid tumors, Versamune MUC1 for prostate, breast, and other MUC1-expressing cancers, and preclinical efforts in colorectal cancer, metastatic breast cancer, and universal influenza vaccines. PDS Biotechnology Corporation operates primarily in the United States with a focus on oncology and infectious diseases, serving patients with advanced and recurrent cancers through clinical trials targeting unmet needs in immunotherapy. Founded in 2005 and headquartered in Princeton, New Jersey, the company maintains a research-driven model with no noted subsidiaries or parent relationships. Recent developments include the initiation of the VERSATILE-003 Phase 3 pivotal trial for PDS0101 in combination with pembrolizumab for recurrent/metastatic HPV16-positive head and neck squamous cell cancer in March 2025 following FDA clearance and Fast Track designation; completion of enrollment and topline survival data from the VERSATILE-002 Phase 2 trial showing median overall survival of 39.3 months in November 2025; FDA clearance of an IND for Versamune MUC1 combined with PDS01ADC in metastatic breast cancer in March 2025; expansion of the PDS01ADC Phase 2 colorectal cancer cohort in July 2025; up to $11.1 million registered direct offering in November 2025 and a prior $22 million offering in February 2025 to fund clinical advancement; and a scheduled Type C meeting with the FDA in December 2025 to discuss expedited approval pathways for PDS0101.
Company News
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
PDS Biotech Reports Second Quarter 2026 Financial Results
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology Q1 Earnings Call Highlights
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript